Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
festuca elatior pollen extract, depigmented polymerized is an allergen immunotherapy (AIT) product developed by LETI Pharma. It consists of pollen extracts from Meadow Fescue (Festuca elatior) that have undergone a depigmentation process to remove non-allergenic components like pigments and flavonoids, followed by polymerization with glutaraldehyde. This chemical modification creates 'allergoids,' which exhibit significantly reduced IgE-binding capacity, thereby lowering the risk of systemic allergic reactions during administration. Despite the reduced allergenicity, the extract retains its immunogenicity, stimulating T-cell responses and inducing the production of allergen-specific IgG4 antibodies to promote long-term clinical tolerance. It is primarily indicated for the treatment of allergic rhinoconjunctivitis and allergic asthma triggered by grass pollen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on festuca elatior pollen extract, depigmented polymerized.